amvuttra
(VUTRISIRAN)Alnylam Pharmaceuticals, Inc.
Usage: AMVUTTRA is indicated for treating the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.
Alnylam Pharmaceuticals, Inc. drugs
4 results
givlaari
(givosiran sodium)Alnylam Pharmaceuticals, Inc.Usage: GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).onpattro
(patisiran)Alnylam Pharmaceuticals, Inc.Usage: ONPATTRO is indicated for treating the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.oxlumo
(lumasiran)Alnylam Pharmaceuticals, Inc.Usage: OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to reduce urinary and plasma oxalate levels in both pediatric and adult patients.